- Home
- BIRD vs HLVX Comparison
BIRD vs HLVX Comparison
Compare BIRD & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIRD
- HLVX
- Stock Information
- Founded
- BIRD 2015
- HLVX 2020
- Country
- BIRD United States
- HLVX United States
- Employees
- BIRD N/A
- HLVX N/A
- Industry
- BIRD Apparel
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- BIRD Consumer Discretionary
- HLVX Health Care
- Exchange
- BIRD Nasdaq
- HLVX Nasdaq
- Market Cap
- BIRD 89.7M
- HLVX 104.3M
- IPO Year
- BIRD 2021
- HLVX 2022
- Fundamental
- Price
- BIRD $7.03
- HLVX $2.08
- Analyst Decision
- BIRD Buy
- HLVX Hold
- Analyst Count
- BIRD 2
- HLVX 1
- Target Price
- BIRD $11.00
- HLVX $2.00
- AVG Volume (30 Days)
- BIRD 71.5K
- HLVX 829.7K
- Earning Date
- BIRD 08-07-2025
- HLVX 08-06-2025
- Dividend Yield
- BIRD N/A
- HLVX N/A
- EPS Growth
- BIRD N/A
- HLVX N/A
- EPS
- BIRD N/A
- HLVX N/A
- Revenue
- BIRD $170,646,000.00
- HLVX N/A
- Revenue This Year
- BIRD N/A
- HLVX N/A
- Revenue Next Year
- BIRD $5.16
- HLVX N/A
- P/E Ratio
- BIRD N/A
- HLVX N/A
- Revenue Growth
- BIRD N/A
- HLVX N/A
- 52 Week Low
- BIRD $3.93
- HLVX $1.34
- 52 Week High
- BIRD $18.33
- HLVX $2.17
- Technical
- Relative Strength Index (RSI)
- BIRD 34.55
- HLVX 52.92
- Support Level
- BIRD $6.55
- HLVX $2.07
- Resistance Level
- BIRD $10.54
- HLVX $2.10
- Average True Range (ATR)
- BIRD 0.78
- HLVX 0.04
- MACD
- BIRD -0.36
- HLVX -0.01
- Stochastic Oscillator
- BIRD 22.28
- HLVX 50.00
About BIRD Allbirds Inc.
Allbirds Inc is a lifestyle brand that innovates with naturally derived materials to make footwear and apparel products in a better way, while treading lighter on the planet. Its primary source of revenue is from sales of shoes and apparel products. The majority of the revenue is derived from United States.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.